Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Nelke

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
Frontiers in Immunology|January 9, 2023
Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumabSaskia Räuber, Alice Willison, Melanie Korsen, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 5, 2022
Eculizumab versus rituximab in generalised myasthenia gravisChristopher Nelke, Christina B Schroeter, Frauke Stascheit, et al.
Nature Communications|May 15, 2024
Cell-mediated cytotoxicity within CSF and brain parenchyma in spinal muscular atrophy unaltered by nusinersen treatmentI-Na Lu, Phyllis Fung-Yi Cheung, Michael Heming, et al.
Journal of Autoimmunity|January 9, 2023
Cerebrospinal fluid proteomics indicates immune dysregulation and neuronal dysfunction in antibody associated autoimmune encephalitisSaskia Räuber, Christina B Schroeter, Christine Strippel, et al.
Acta Neuropathologica Communications|February 5, 2026
Proteomic profiles in inclusion body myositis and polymyositis with mitochondrial pathologyFelix Kleefeld, Christina B Schroeter, Donya Abdennebi, et al.
Neurological Research and Practice|May 13, 2026
Multicentric prognostic observational study on biomarker profile in immunotherapy-naïve patients with highly active generalized myasthenia gravis (PROGNO-MG): a study protocolFelix Kohle, Franz Felix Konen, Ulrike Grittner, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 11, 2025
C5 complement inhibition versus FcRn modulation in generalised myasthenia gravisNiklas Huntemann, Lea Gerischer, Meret Herdick, et al.
Journal of Neuroinflammation|November 9, 2022
Cladribine treatment improves cortical network functionality in a mouse model of autoimmune encephalomyelitisChristina B Schroeter, Leoni Rolfes, K S Sophie Gothan, et al.
Acta Neuropathologica|June 18, 2024
Inter-alpha-trypsin inhibitor heavy chain H3 is a potential biomarker for disease activity in myasthenia gravisChristina B Schroeter, Christopher Nelke, Frauke Stascheit, et al.
Journal of Neurology|July 11, 2024
Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohortPaula Quint, Christina B Schroeter, Felix Kohle, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Frontiers in Immunology|January 9, 2023
Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumabSaskia Räuber, Alice Willison, Melanie Korsen, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 5, 2022
Eculizumab versus rituximab in generalised myasthenia gravisChristopher Nelke, Christina B Schroeter, Frauke Stascheit, et al.
Nature Communications|May 15, 2024
Cell-mediated cytotoxicity within CSF and brain parenchyma in spinal muscular atrophy unaltered by nusinersen treatmentI-Na Lu, Phyllis Fung-Yi Cheung, Michael Heming, et al.
Journal of Autoimmunity|January 9, 2023
Cerebrospinal fluid proteomics indicates immune dysregulation and neuronal dysfunction in antibody associated autoimmune encephalitisSaskia Räuber, Christina B Schroeter, Christine Strippel, et al.
Acta Neuropathologica Communications|February 5, 2026
Proteomic profiles in inclusion body myositis and polymyositis with mitochondrial pathologyFelix Kleefeld, Christina B Schroeter, Donya Abdennebi, et al.
Neurological Research and Practice|May 13, 2026
Multicentric prognostic observational study on biomarker profile in immunotherapy-naïve patients with highly active generalized myasthenia gravis (PROGNO-MG): a study protocolFelix Kohle, Franz Felix Konen, Ulrike Grittner, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 11, 2025
C5 complement inhibition versus FcRn modulation in generalised myasthenia gravisNiklas Huntemann, Lea Gerischer, Meret Herdick, et al.
Journal of Neuroinflammation|November 9, 2022
Cladribine treatment improves cortical network functionality in a mouse model of autoimmune encephalomyelitisChristina B Schroeter, Leoni Rolfes, K S Sophie Gothan, et al.
Acta Neuropathologica|June 18, 2024
Inter-alpha-trypsin inhibitor heavy chain H3 is a potential biomarker for disease activity in myasthenia gravisChristina B Schroeter, Christopher Nelke, Frauke Stascheit, et al.
Journal of Neurology|July 11, 2024
Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohortPaula Quint, Christina B Schroeter, Felix Kohle, et al.
Pageof 8